Hormonal
Semaglutide (2.4 mg/weekly) significantly reduces the risk of major adverse cardiovascular events (MACE) in patients with overweight or obesity without diabetes, while also producing substantial weight loss and improving heart failure symptoms in those with preserved ejection fraction.
If you have heart disease or high risk for it, along with excess weight, semaglutide (Ozempic/Wegovy) is a highly effective treatment. It is taken as a once-weekly injection, starting at a low dose and increasing over 4 months to 2.4 mg. It significantly lowers your risk of heart attack and stroke, helps you lose about 9-13% of your body weight, and improves heart failure symptoms if you have them. Common side effects like nausea are usually temporary and manageable.
Treatment with semaglutide for approximately 33 months resulted in a mean body weight loss of 9.4% and a 20% reduction of the 3P-MACE composite risk (HR 0.80; 95% CI 0.72 to 0.90; p < 0.001)... The mean change in KCCQ-CSS at week 52... was 16.6 points in the semaglutide group... The other dual primary endpoint, the mean percentage change in body weight at week 52 was − 13.3% in the semaglutide group
Why this rating
Based on large-scale, randomized, placebo-controlled outcome trials (SELECT, STEP-HFpEF) with rigorous endpoints.
Source
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes
Oliver Schnell et al. · Cardiovascular Diabetology · 2024
DOI 10.1186/s12933-024-02180-8
More from this paper
- Dapagliflozin (10 mg daily) improves cardiometabolic outcomes in patients hospitalized for myocardial infarction, regardless of diabetes status, by reducing the risk of heart failure hospitalization and death.Strong
- Bempedoic acid (180 mg daily) reduces major adverse cardiovascular events (MACE) in high-risk patients who are unable or unwilling to take statins, primarily by lowering LDL cholesterol and reducing coronary revascularization needs.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →